#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Philadelphia chromosome positive Lip and/or oral cavity cancer Pericarditis Postprandial hypoglycaemia Pustular psoriasis Complex regional pain syndrome Osteogenesis imperfecta Loeys-Dietz syndrome Osteosarcoma Richter's syndrome Peritoneal neoplasm Leukocyte adhesion deficiency Oesophageal carcinoma Chronic myeloid leukaemia (in remission) Glomerulonephritis rapidly progressive More trials…

    Learn about Rare Diseases

    Pituitary-dependent Cushing’s syndrome – Diagnostics Epidermolysis bullosa – Basic Information Ocular melanoma – Basic Information Vascular malformation Biotinidase deficiency Glycogen storage disease type II – Basic Information Langerhans cell sarcoma Rhabdomyosarcoma recurrent – Basic Information Malignant fibrous histiocytoma – Trials in Disease Antisynthetase syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Donepezil Esk-001 Metyrapone Bp Tasquinimod Tislelizumab Azelastine Exidavnemab Dexrazoxane Nmd670 Lysine Acetate Lovo-A Lenograstim Piritramide Fluvastatin Adct-402 Quc398 Pioglitazone STREPTOCOCCUS PYOGENES Testosterone Levomepromazine Hydrochloride More therapies…

    Learn about Your Condition

    Heparin resistance Critical illness Spinal cord injury cervical Organ donor Cutaneous calcification Osteosarcoma Salivary gland cancer Uterine leiomyosarcoma Transient ischaemic attack Triple positive breast cancer Rabies Breast proliferative changes Schizophrenia Hodgkin's disease refractory Diabetic foot infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Elacestrant
    • Abemaciclib
    Belgium France Germany Greece Italy Spain

  • Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Interstitial lung disease
    Investigated Drugs:
    • Belimumab
    Belgium France Germany Greece Italy The Netherlands +1

  • Phase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hyperparathyroidism secondary
    Investigated Drugs:
    • Etelcalcetide
    Belgium Czechia Germany Greece Italy Poland +2

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium France Germany Hungary Italy +3

  • A study of SKB410, enfortumab vedotin, and pembrolizumab combination for patients with locally advanced or metastatic urothelial cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Pembrolizumab
    • SKB410
    France The Netherlands Spain

  • Study of ublituximab compared to fingolimod for children and teenagers aged 10 to 17 years with relapsing multiple sclerosis

    Recruiting

    4 1 1
    Investigated Drugs:
    • Fingolimod
    • Ublituximab
    Poland Slovakia
Previous Page
1 … 60 61 62 63 64 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!